HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

被引：45

作者：

Sone, H

Takahashi, A

Shimano, H

Ishibashi, S

Yoshino, G

Morisaki, N

Saito, Y

Kawazu, S

Teramoto, T

Fujita, T

Shiba, T

Iwamoto, Y

Kuzuya, N

Akanuma, Y

Yamada, N

机构：

[1] Univ Tsukuba, Inst Clin Med, Dept Internal Med Endocrinol Metab, Tsukuba, Ibaraki 3058575, Japan

[2] Jichi Med Sch, Dept Internal Med, Tochigi 3290498, Japan

[3] Toho Univ, Sch Med, Dept Lab Med, Tokyo 1438541, Japan

[4] Chiba Univ, Dept Internal Med 2, Chiba 2608677, Japan

[5] Saitama Med Ctr, Saitama Med Sch, Dept Total Hlth Management, Kawagoe, Saitama 3508550, Japan

[6] Teikyo Univ, Dept Internal Med, Tokyo 1738606, Japan

[7] Univ Tokyo, Branch Hosp, Dept Internal Med, Tokyo 1128688, Japan

[8] Mitsui Mem Hosp, Dept Internal Med, Tokyo 1018643, Japan

[9] Tokyo Womens Univ, Sch Med, Ctr Diabet, Tokyo 1628666, Japan

[10] Asahi Life Fdn, Inst Adult Dis & Res, Tokyo 1000005, Japan

[11] Asahi Life Fdn, Inst Diabet Care & Res, Tokyo 1000005, Japan

来源：

LIFE SCIENCES | 2002年 / 71卷 / 20期

基金：

日本学术振兴会;

关键词：

type; 2; diabetes; dyslipidemia; 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor; pitavastatin; remnant-like particle cholesterol (RLP-C); small dense low density lipoprotein (LDL);

D O I：

10.1016/S0024-3205(02)02038-6

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Patients with type 2 diabetes are known to have abnormalities in their remnant metabolism and low density lipoprotein (LDL) subfraction pattern, with a preponderance of small dense LDL. The effects of pitavastatin, a newly synthesized 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, on lipoprotein profiles in patients with type 2 diabetes were determined. Thirty-three patients were treated with pitavastatin with a daily dose of 2 mg for 8 weeks. After treatment, triglyceride, total and LDL cholesterol were significantly reduced by 28.7 +/- 36.7%, 25.2 +/- 14.3% and 36.1 +/- 14.3%, respectively. Remnant-like particle cholesterol (RLP-C), an independent risk factor for CAD which is known to be elevated in diabetic patients, was also significantly reduced - 30.9 +/- 30.5%) by the treatment and this decrease correlated well with the decrease in triglyceride level. The proportion of small dense LDL, which is known for its atherogenisity, decreased from 29.9 +/- 26.2% to 19.7 +/- 22.7% and the mean LDL particle size significantly increased from 26.36 +/- 1.13 nm to 27.10 +/- 1.36 nm. Pitavastatin, which is known to improve triglyceride levels and cholesterol levels, also improves RLP-C level and LDL subfraction profiles, and this in turn may reduce the cardiovascular risk in patients with type 2 diabetes and dyslipidemia. (C) 2002 Elsevier Science Inc. All rights reserved.

引用

页码：2403 / 2412

页数：10